Table 4.
Multivariate analysis of progression-free and overall survival for the study population
| Progression-free survival | Overall survival | |||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Overall study population (n = 31) | ||||
| TMBhigh | 0.70 (0.18–2.67) | 0.60 | 0.45 (0.11–1.79) | 0.26 |
| ECOG 1 | 2.00 (0.76–5.27) | 0.16 | 2.92 (1.07–7.98) | 0.04 |
| ECOG 2 | 5.92 (1.27–27.59) | 0.02 | 8.05 (1.60–40.50) | 0.01 |
| Intermediate disease burden | 4.43 (1.25–15.76) | 0.02 | 10.61 (2.50–45.04) | 0.0014 |
| High disease burden | 4.87 (1.28–18.60) | 0.02 | 5.30 (1.30–21.61) | 0.02 |
| Patients with available PD-L1 status (n = 15) | ||||
| TMBhigh | 0.49 (0.10–2.46) | 0.39 | 0.31 (0.06–1.58) | 0.16 |
| PD-L1 positive | 0.71 (0.20–2.50) | 0.60 | 0.30 (0.07–1.22) | 0.09 |
The analysis comprised a multivariate Cox regression model that included the relevant prognostic factors. Source data are provided as a Source Data file.